ARNOLD E. POSTLETHWAITE, M.D., A.B.

Goodman Professor

Office: G326 Coleman College Of Medicine Building
Tel: (901) 448-5774
apostlet@uthsc.edu

Education

  • , Duke University Medical Center, Durham, NC (Howard Hughes Medical Institute), Med. Res./Rheum. Fellow
  • , Tulane Div. Charity Hospital, New Orleans, LA, Intern & Resident
  • M.D., Cornell University Medical College, NY, NY, Medicine
  • B.S., West Virginia University, Morgantown, WV, Pre-Medicine

Research interest/specialty

Biomedical and and molecular biological analysis of connective tissue disease.

Research interest/specialty

Biomedical and and molecular biological analysis of connective tissue disease.

Publications

  1. Wong WK, Boscardin WJ, Postlethwaite AE, Furst DE. Handling missing data issues in clinical trials for rheumatic diseases.. Contemp Clin Trials, 32 (1), 1-9, 2011.
  2. Slominski, AT, Li, W, Bhattacharya, SK, Smith, RA, Johnson, PL, Chen, J, Nelson, KE, Tuckey, RC, Miller, D, Jiao, Y, Gu, W, Postlethwaite, AE. Vitamin D Analogs 17,20S(OH)(2)pD and 17,20R(OH)(2)pD Are Noncalcemic and Exhibit Antifibrotic Activity. J Invest Dermatol, 2011.
  3. Nashid, M, Khanna, PP, Furst, DE, Clements, PJ, Maranian, P, Seibold, J, Postlethwaite, AE, Louie, JS, Mayes, MD, Agrawal, H, Khanna, D, ,. Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trials. Rheumatology (Oxford), 2010.
  4. Atamas, SP, Luzina, IG, Ingels, J, Choi, J, Wong, WK, Furst, DE, Clements, PJ, , , Postlethwaite, AE. Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma). Clin Exp Immunol, 161 (3), 426-35, 2010.
  5. Pattanaik, D, Postlethwaite, AE. A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis. Discov Med, 10 (51), 161-7, 2010.
  6. Postlethwaite, AE, Harris, LJ, Raza, SH, Kodura, S, Akhigbe, T. Pharmacotherapy of systemic sclerosis. Expert Opin Pharmacother, 11 (5), 789-806, 2010.
  7. Kaldas, M, Khanna, PP, Furst, DE, Clements, PJ, Kee Wong, W, Seibold, JR, Postlethwaite, AE, Khanna, D, ,. Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials. Rheumatology (Oxford), 48 (9), 1143-6, 2009.
  8. Amjadi, S, Maranian, P, Furst, DE, Clements, PJ, Wong, WK, Postlethwaite, AE, Khanna, PP, Khanna, D, ,. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum, 60 (8), 2490-8, 2009.
  9. Khanna, D, Clements, PJ, Postlethwaite, AE, Furst, DE. Does Incorporation of Aids and Devices Make a Difference in the Score of the Health Assessment Questionnaire-Disability Index? Analysis from a Scleroderma Clinical Trial. J Rheumatol, 35 (3), 466-468, 2008.
  10. Chiang, TM, Postlethwaite, AE. Alteration in protein kinase B (AKT) activity in platelets from patients with systemic sclerosis. Thromb Res, 2008.
  11. Postlethwaite, AE, Chiang, TM. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol, 19 (6), 574-9, 2007.
  12. Khanna, D, Furst, DE, Wong, WK, Tsevat, J, Clements, PJ, Park, GS, Postlethwaite, AE, Ahmed, M, Ginsburg, S, Hays, RD, ,. Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Qual Life Res, 16 (6), 1083-92, 2007.
  13. Chiang, TM, Postlethwaite, AE. A cell model system to study regulation of phosphotidylinositol 3-kinase and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune cells from patients with systemic sclerosis. Biochim Biophys Acta, 1770 (8), 1181-6, 2007.
  14. Carbone, LD, Warrington, KJ, Barrow, KD, Pugazhenthi, M, Watsky, MA, Somes, G, Ingels, J, Postlethwaite, AE. Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. Clin Exp Immunol, 146 (3), 371-80, 2006.
  15. Kanangat, S, Postlethwaite, AE, Higgins, GC, Hasty, KA. Novel functions of intracellular IL-1ra in human dermal fibroblasts: implications in the pathogenesis of fibrosis. J Invest Dermatol, 126 (4), 756-65, 2006.
  16. Warrington, KJ, Nair, U, Carbone, LD, Kang, AH, Postlethwaite, AE. Characterisation of the immune response to type I collagen in scleroderma. Arthritis Res Ther, 8 (4), R136, 2006.
  17. Chiang, TM, Postlethwaite, AE. Increase in phosphotidylinositide-3 kinase activity by nitrotyrosylation of lysates of platelets from patients with systemic sclerosis. Biochim Biophys Acta, 1760 (1), 32-7, 2006.
  18. Takagi, K, Takagi, M, Kanangat, S, Warrington, KJ, Shigemitsu, H, Postlethwaite, AE. Modulation of TNF-alpha gene expression by IFN-gamma and pamidronate in murine macrophages: regulation by STAT1-dependent pathways. J Immunol, 174 (4), 1801-10, 2005.
  19. Chiang, TM, Takayama, H, Postlethwaite, AE. Increase in platelet non-integrin type I collagen receptor in patients with systemic sclerosis. Thromb Res, 117 (3), 299-306, 2005.
  20. Postlethwaite, AE, Shigemitsu, H, Kanangat, S. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol, 16 (6), 733-8, 2004.
  21. Ahokas, RA, Warrington, KJ, Gerling, IC, Sun, Y, Wodi, LA, Herring, PA, Lu, L, Bhattacharya, SK, Postlethwaite, AE, Weber, KT. Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res, 93 (10), e124-35, 2003.
  22. Weber, KT, Sun, Y, Wodi, LA, Munir, A, Jahangir, E, Ahokas, RA, Gerling, IC, Postlethwaite, AE, Warrington, KJ. Toward a broader understanding of aldosterone in congestive heart failure. J Renin Angiotensin Aldosterone Syst, 4 (3), 155-63, 2003.
  23. Gerling, IC, Sun, Y, Ahokas, RA, Wodi, LA, Bhattacharya, SK, Warrington, KJ, Postlethwaite, AE, Weber, KT. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol, 285 (2), H813-21, 2003.
  24. Weber, KT, Gerling, IC, Kiani, MF, Guntaka, RV, Sun, Y, Ahokas, RA, Postlethwaite, AE, Warrington, KJ. Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr Drug Targets, 4 (6), 505-16, 2003.
  25. Sun, Y, Kiani, MF, Postlethwaite, AE, Weber, KT. Infarct scar as living tissue. Basic Res Cardiol, 97 (5), 343-7, 2002.
  26. Myers, LK, Higgins, GC, Finkel, TH, Reed, AM, Thompson, JW, Walton, RC, Hendrickson, J, Kerr, NC, Pandya-Lipman, RK, Shlopov, BV, Stastny, P, Postlethwaite, AE, Kang, AH. Juvenile arthritis and autoimmunity to type II collagen. Arthritis Rheum, 44 (8), 1775-81, 2001.
  27. Postlethwaite, AE. Can we induce tolerance in rheumatoid arthritis. Curr Rheumatol Rep, 3 (1), 64-9, 2001.
  28. Myers, LK, Kang, AH, Postlethwaite, AE, Rosloniec, EF, Morham, SG, Shlopov, BV, Goorha, S, Ballou, LR. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum, 43 (12), 2687-93, 2000.
  29. McKown, KM, Carbone, LD, Bustillo, J, Seyer, JM, Kang, AH, Postlethwaite, AE. Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum, 43 (5), 1054-61, 2000.
  30. Higgins, GC, Wu, Y, Postlethwaite, AE. Intracellular IL-1 receptor antagonist is elevated in human dermal fibroblasts that overexpress intracellular precursor IL-1 alpha. J Immunol, 163 (7), 3969-75, 1999.
  31. McKown, KM, Carbone, LD, Kaplan, SB, Aelion, JA, Lohr, KM, Cremer, MA, Bustillo, J, Gonzalez, M, Kaeley, G, Steere, EL, Somes, GW, Myers, LK, Seyer, JM, Kang, AH, Postlethwaite, AE. Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum, 42 (6), 1204-8, 1999.
  32. Postlethwaite, AE. Bidirectional interactions between T cells and the extracellular matrix. Transpl Immunol, 5 (4), 289-91, 1997.
  33. Solomon, SS, Mishra, SK, Cwik, C, Rajanna, B, Postlethwaite, AE. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells. Horm Metab Res, 29 (8), 379-82, 1997.
  34. Solomon, SS, Mishra, SK, Palazzolo, MR, Postlethwaite, AE, Seyer, JM. Identification of specific sites in the TNF-alpha molecule promoting insulin resistance in H-411E cells. J Lab Clin Med, 130 (2), 139-46, 1997.
  35. Higgins, GC, Postlethwaite, AE. Synovial fluid from patients with rheumatoid arthritis contains a unique inhibitor of interleukin 1 alpha. J Rheumatol, 23 (6), 965-73, 1996.
  36. Postlethwaite, AE. Connective tissue metabolism including cytokines in scleroderma. Curr Opin Rheumatol, 7 (6), 535-40, 1995.
  37. Ballou, LR, Postlethwaite, AE, Kang, AH. The Effect of Misoprostol on Arachidonic Acid Mobilization, Prostaglandin E(2), Production, and IL-1beta Signaling. Am J Ther, 2 (9), 630-636, 1995.
  38. Postlethwaite, AE, Seyer, JM. Identification of a chemotactic epitope in human transforming growth factor-beta 1 spanning amino acid residues 368-374. J Cell Physiol, 164 (3), 587-92, 1995.
  39. Postlethwaite, AE. Role of T cells and cytokines in effecting fibrosis. Int Rev Immunol, 12 (2-4), 247-58, 1995.
  40. Postlethwaite, AE, Raghow, R, Stricklin, G, Ballou, L, Sampath, TK. Osteogenic protein-1, a bone morphogenic protein member of the TGF-beta superfamily, shares chemotactic but not fibrogenic properties with TGF-beta. J Cell Physiol, 161 (3), 562-70, 1994.
  41. Postlethwaite, AE. Connective tissue metabolism including cytokines in scleroderma. Curr Opin Rheumatol, 6 (6), 616-20, 1994.
  42. Higgins, GC, Foster, JL, Postlethwaite, AE. Interleukin 1 beta propeptide is detected intracellularly and extracellularly when human monocytes are stimulated with LPS in vitro. J Exp Med, 180 (2), 607-14, 1994.
  43. Postlethwaite, AE. Connective tissue metabolism including cytokines in scleroderma. Curr Opin Rheumatol, 5 (6), 766-72, 1993.
  44. Postlethwaite, AE, Holness, MA, Katai, H, Raghow, R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest, 90 (4), 1479-85, 1992.
  45. Kapás, L, Hong, L, Cady, AB, Opp, MR, Postlethwaite, AE, Seyer, JM, Krueger, JM. Somnogenic, pyrogenic, and anorectic activities of tumor necrosis factor-alpha and TNF-alpha fragments. Am J Physiol, 263 (3 Pt 2), R708-15, 1992.
  46. Opp, MR, Postlethwaite, AE, Seyer, JM, Krueger, JM. Interleukin 1 receptor antagonist blocks somnogenic and pyrogenic responses to an interleukin 1 fragment. Proc Natl Acad Sci U S A, 89 (9), 3726-30, 1992.
  47. Armendariz-Borunda, J, Seyer, JM, Postlethwaite, AE, Kang, AH. Kupffer cells from carbon tetrachloride-injured rat livers produce chemotactic factors for fibroblasts and monocytes: the role of tumor necrosis factor-alpha. Hepatology, 14 (5), 895-900, 1991.
  48. Postlethwaite, AE, Seyer, JM. Fibroblast chemotaxis induction by human recombinant interleukin-4. Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70-88 and 89-122. J Clin Invest, 87 (6), 2147-52, 1991.
  49. Ballou, LR, Barker, SC, Postlethwaite, AE, Kang, AH. Interleukin 1 stimulates phosphatidylinositol kinase activity in human fibroblasts. J Clin Invest, 87 (1), 299-304, 1991.
  50. Ballou, LR, Barker, SC, Postlethwaite, AE, Kang, AH. Sphingosine potentiates IL-1-mediated prostaglandin E2 production in human fibroblasts. J Immunol, 145 (12), 4245-51, 1990.
  51. Postlethwaite, AE, Seyer, JM. Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor alpha (TNF-alpha) and a synthetic TNF-alpha 31-68 peptide. J Exp Med, 172 (6), 1749-56, 1990.
  52. Obal, F, Opp, M, Cady, AB, Johannsen, L, Postlethwaite, AE, Poppleton, HM, Seyer, JM, Krueger, JM. Interleukin 1 alpha and an interleukin 1 beta fragment are somnogenic. Am J Physiol, 259 (3 Pt 2), R439-46, 1990.
  53. Postlethwaite, AE. Early immune events in scleroderma. Rheum Dis Clin North Am, 16 (1), 125-39, 1990.
  54. Drake, S, Massie, JD, Postlethwaite, AE, Palmieri, GM. Pamidronate sodium and calcitonin-resistant Paget's disease. Immediate response in a patient. Arch Intern Med, 149 (2), 401-3, 1989.
  55. Postlethwaite, AE, Smith, GN, Lachman, LB, Endres, RO, Poppleton, HM, Hasty, KA, Seyer, JM, Kang, AH. Stimulation of glycosaminoglycan synthesis in cultured human dermal fibroblasts by interleukin 1. Induction of hyaluronic acid synthesis by natural and recombinant interleukin 1s and synthetic interleukin 1 beta peptide 163-171. J Clin Invest, 83 (2), 629-36, 1989.
  56. Postlethwaite, AE, Raghow, R, Stricklin, GP, Poppleton, H, Seyer, JM, Kang, AH. Modulation of fibroblast functions by interleukin 1: increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 alpha and beta. J Cell Biol, 106 (2), 311-8, 1988.
  57. Postlethwaite, AE, Kang, AH. Advantages and limitations of in vitro models of wound healing and tissue repair. Prog Clin Biol Res, 266, 237-42, 1988.